Ticker

March 18, 2026 Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff Study, designed to evaluate the clinical performance of…

February 5, 2026 Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update                                                                         COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no.